Sanofi reported an impressive increase in its profit, credited to the rising demand for seasonal vaccines and ongoing success of its asthma drug, Dupixent.
CEO Paul Hudson emphasized Sanofi's commitment to drug development, stating, 'We are pushing a dozen potential top-selling medicines through costly clinical trials to expand our product offerings beyond Dupixent.'
Dupixent sales soared by 24% to approximately €3.5 billion in the quarter, with expanded indications boosting its revenue potential in the market.
Sanofi's CFO downplayed competition from Merck's RSV treatment, confidently asserting that Sanofi's Beyfortus has demonstrated superior efficacy and efficacy in protecting thousands of babies.
Collection
[
|
...
]